QRG Capital Management Inc. Has $1.10 Million Position in Illumina, Inc. (NASDAQ:ILMN)

QRG Capital Management Inc. grew its position in Illumina, Inc. (NASDAQ:ILMN) by 21.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,411 shares of the life sciences company’s stock after purchasing an additional 1,502 shares during the period. QRG Capital Management Inc.’s holdings in Illumina were worth $1,097,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in ILMN. UMB Bank n.a. grew its stake in Illumina by 7.0% during the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after buying an additional 88 shares during the last quarter. Integrated Advisors Network LLC grew its position in Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after acquiring an additional 90 shares during the last quarter. Texas Permanent School Fund Corp grew its position in Illumina by 0.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 32,818 shares of the life sciences company’s stock worth $4,507,000 after acquiring an additional 114 shares during the last quarter. Institute for Wealth Management LLC. raised its position in Illumina by 4.6% in the 2nd quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company’s stock valued at $285,000 after purchasing an additional 119 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV boosted its stake in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 2.6 %

Shares of ILMN stock opened at $151.09 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 0.86. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $156.66. The firm has a fifty day moving average of $138.09 and a 200-day moving average of $123.56.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.33 earnings per share. Sell-side analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Scotiabank cut their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a report on Thursday, August 15th. Leerink Partners boosted their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Piper Sandler decreased their price target on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Daiwa America upgraded shares of Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Finally, Barclays upped their price objective on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $162.18.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.